Sign In
Buy PGEN
$6.27
+0.330 (+5.56%)
At Close: Jul 31, 2026
3 Penny Stocks To Buy With Just $50
07:54am, Sunday, 15'th Sep 2024
Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
3 Penny Stocks to Buy With $500
10:20am, Friday, 30'th Aug 2024
Are you interested in investing in penny stocks?
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.
Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript
07:03pm, Wednesday, 14'th Aug 2024
Precigen, Inc. (NASDAQ:PGEN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Harry Thomasian - CFO Phil Tenn
Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates
06:31pm, Wednesday, 14'th Aug 2024
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
04:05pm, Wednesday, 14'th Aug 2024
– In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
08:00am, Friday, 09'th Aug 2024
GERMANTOWN, Md. , Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
09:30pm, Wednesday, 07'th Aug 2024
GERMANTOWN, Md. , Aug. 7, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public offeri
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
11:06am, Wednesday, 07'th Aug 2024
Precigen (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen Announces Proposed $30 Million Public Offering of Common Stock
04:04pm, Tuesday, 06'th Aug 2024
GERMANTOWN, Md. , Aug. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock.
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
04:01pm, Tuesday, 06'th Aug 2024
– PRGN-2012 is on track for a rolling BLA submission under an accelerated approval pathway; patient enrollment initiated in the confirmatory clinical trial – GERMANTOWN, Md. , Aug. 6, 2024 /PRNews
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
08:01am, Tuesday, 23'rd Jul 2024
– Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md. , July 23, 2024 /P
– Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-20
GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
06:20pm, Tuesday, 14'th May 2024
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
